SELLAS Life Sciences Group, Inc. (SLS): Price and Financial Metrics


SELLAS Life Sciences Group, Inc. (SLS): $1.38

0.13 (+10.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SLS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SLS POWR Grades

  • Growth is the dimension where SLS ranks best; there it ranks ahead of 64.92% of US stocks.
  • The strongest trend for SLS is in Stability, which has been heading down over the past 177 days.
  • SLS's current lowest rank is in the Stability metric (where it is better than 3.73% of US stocks).

SLS Stock Summary

  • For SLS, its debt to operating expenses ratio is greater than that reported by just 6.77% of US equities we're observing.
  • With a price/sales ratio of 34.81, SELLAS LIFE SCIENCES GROUP INC has a higher such ratio than 95.65% of stocks in our set.
  • Revenue growth over the past 12 months for SELLAS LIFE SCIENCES GROUP INC comes in at -86.84%, a number that bests merely 1.63% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to SELLAS LIFE SCIENCES GROUP INC, a group of peers worth examining would be FNCH, APVO, IPHA, AEZS, and ANGN.
  • SLS's SEC filings can be seen here. And to visit SELLAS LIFE SCIENCES GROUP INC's official web site, go to www.sellaslifesciences.com.

SLS Valuation Summary

  • SLS's price/earnings ratio is -0.8; this is 103.45% lower than that of the median Healthcare stock.
  • SLS's price/earnings ratio has moved up 11.3 over the prior 183 months.

Below are key valuation metrics over time for SLS.

Stock Date P/S P/B P/E EV/EBIT
SLS 2023-03-24 34.8 7.2 -0.8 -0.4
SLS 2023-03-23 34.5 7.1 -0.8 -0.4
SLS 2023-03-22 35.1 7.2 -0.8 -0.5
SLS 2023-03-21 36.8 7.6 -0.9 -0.5
SLS 2023-03-20 36.2 7.5 -0.9 -0.5
SLS 2023-03-17 38.2 7.9 -0.9 -0.5

SLS Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at -44.86%.
  • Its year over year net income to common stockholders growth rate is now at -133.34%.
  • The 5 year net income to common stockholders growth rate now stands at -44.86%.
SLS's revenue has moved up $1,000,000 over the prior 67 months.

The table below shows SLS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1 -23.633 -38.778
2022-06-30 1 -23.765 -38.841
2022-03-31 2.9 -22.902 -35.04
2021-12-31 7.6 -26.021 -20.699
2021-09-30 9.5 -17.621 -17.817
2021-06-30 9.5 -15.372 -15.205

SLS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SLS has a Quality Grade of D, ranking ahead of 22.65% of graded US stocks.
  • SLS's asset turnover comes in at 0.255 -- ranking 173rd of 680 Pharmaceutical Products stocks.
  • ZSAN, MNOV, and OVID are the stocks whose asset turnover ratios are most correlated with SLS.

The table below shows SLS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.255 0.979 -3.728
2021-03-31 0.254 0.987 -4.352
2020-12-31 0.079 1.000 -5.135
2020-09-30 0.000 NA -4.595
2020-06-30 0.000 NA -4.552
2020-03-31 0.000 NA -4.415

SLS Price Target

For more insight on analysts targets of SLS, see our SLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.50 Average Broker Recommendation 1.5 (Moderate Buy)

SLS Stock Price Chart Interactive Chart >

Price chart for SLS

SLS Price/Volume Stats

Current price $1.38 52-week high $7.37
Prev. close $1.25 52-week low $1.17
Day low $1.26 Volume 415,300
Day high $1.41 Avg. volume 446,948
50-day MA $2.42 Dividend yield N/A
200-day MA $2.67 Market Cap 39.06M

SELLAS Life Sciences Group, Inc. (SLS) Company Bio


SELLAS Life Sciences, Ltd. is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.


SLS Latest News Stream


Event/Time News Detail
Loading, please wait...

SLS Latest Social Stream


Loading social stream, please wait...

View Full SLS Social Stream

Latest SLS News From Around the Web

Below are the latest news stories about SELLAS LIFE SCIENCES GROUP INC that investors may wish to consider to help them evaluate SLS as an investment opportunity.

SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update

Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024 Ongoing Phase 1 Study of CDK9 Inhibitor Suggests Broad Therapeutic Window and High Potential for Both Monotherapy and Combination Treatment $20 Million of Gross Proceeds from Capital Raise in February 2023 Adds to Cash Position of $17.1 Million as of December 31, 2022; Additional $13 Million Milestone Payment Expected in 1H 2023 NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:

Yahoo | March 16, 2023

SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal

Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer in the Post-Salvage Setting Immune Response Translated into Clear Clinical Benefit with 70% One-Year Progression-Free Survival Demonstrated in GPS-Treated Patients NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”) today announced that the previously reported results from the final analysis

Yahoo | March 7, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!

William White on InvestorPlace | February 24, 2023

BA Stock Alert: Boeing Halts Deliveries of 787 Dreamliners

Boeing (BA) stock is a hot topic among traders on Friday after the aerospace company halted deliveries of its 787 Dreamliner.

William White on InvestorPlace | February 24, 2023

PIXY Stock Alert: What to Know as ShiftPixy Utilizes ChatGPT for Recruiting

ShiftPixy (PIXY) stock is on the move Friday after the company announced plans to use ChatGPT for recruiting and hiring.

William White on InvestorPlace | February 24, 2023

Read More 'SLS' Stories Here

SLS Price Returns

1-mo -12.10%
3-mo -41.53%
6-mo -31.68%
1-year -79.34%
3-year -20.23%
5-year -99.20%
YTD -41.53%
2022 -57.32%
2021 -4.82%
2020 35.12%
2019 -93.01%
2018 -84.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6777 seconds.